Satisfaction and Quality of Life in Patients With a Diagnosis of Non Valvular Atrial Fibrillation Who Take Rivaroxaban for Stroke Prevention

Trial Profile

Satisfaction and Quality of Life in Patients With a Diagnosis of Non Valvular Atrial Fibrillation Who Take Rivaroxaban for Stroke Prevention

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Atrial fibrillation; Embolism and thrombosis; Stroke
  • Focus Therapeutic Use
  • Acronyms SAFARI
  • Sponsors Bayer
  • Most Recent Events

    • 28 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 Oct 2014 According to the ClinicalTrials.gov, status changed from recruiting to active, no longer recruiting.
    • 03 May 2014 Planned End Date changed from 1 Jun 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top